Novartis International AG http://www.novartis.com Sandoz leads the way with first generic version of 'gold standard' anti-thrombotic Lovenox®[1] 2010-07-23T17:22:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1433879.shtml Novartis receives approval in China for Rasilez, a first-in-class direct renin inhibitor for high blood pressure, the leading preventable cause of death in China 2010-07-20T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1432666.shtml Novartis delivers strong financial performance in second quarter, underpinned by increased momentum in innovation 2010-07-15T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1431809.shtml Plaintiffs and Novartis Pharmaceuticals Corporation, a US subsidiary of Novartis AG, agree to resolve all gender discrimination claims associated with class action 2010-07-14T23:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1431791.shtml Phase III study shows Novartis drug Afinitor® more than doubles time without tumor growth in advanced pancreatic NET patients 2010-07-01T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1428793.shtml Novartis provides progress-update to achieving 77% majority ownership of Alcon 2010-06-30T22:45:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1428790.shtml New Phase II study in gout patients shows Novartis ACZ885 prevented acute flares better than standard anti-inflammatory therapy 2010-06-18T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1424979.shtml FDA approves Tasigna® for newly diagnosed chronic myeloid leukemia patients, data demonstrate major advance over Glivec® 2010-06-18T00:15:56 CET http://www.novartis.com/newsroom/media-releases/en/2010/1424982.shtml FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to treat relapsing remitting MS 2010-06-11T01:05:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1423236.shtml Study at ASCO shows Novartis drug Afinitor® first to shrink SEGA brain tumors in children and adults with tuberous sclerosis 2010-06-05T23:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1421888.shtml